Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.39 |
| ▸ | CA9 | Q16790 | 5/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 3/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP7 | P09237 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26354540 | 1.00 | CA2 (0.39) | CA2CA9CA1CA12ENPP3 | |
| SCHEMBL1824132 | 0.87 | ALDH1A1 (0.41) | CA2CA9CA1CA12ENPP3 | |
| SCHEMBL19716753 | 0.87 | CA1 (0.46) | CA2CA9CA1ALDH1A1PARP10 | |
| SCHEMBL1823010 | 0.87 | CA2 (0.39) | CA2CA9CA1CA12ENPP3 | |
| SCHEMBL6621061 | 0.83 | ENPP3 (0.41) | CA2CA9CA1CA12ENPP3 | |
| SCHEMBL21116730 | 0.83 | ALOX5 (0.42) | CA2CA9CA1CA12ALDH1A1 | |
| SCHEMBL1826771 | 0.83 | CA2 (0.37) | CA2CA9CA1CA12ENPP3 | |
| SCHEMBL19716485 | 0.81 | F9 (0.39) | ALDH1A1 | |
| SCHEMBL19716845 | 0.81 | PARP10 (0.47) | CA2CA9CA1CA12ALDH1A1 | |
| SCHEMBL19734828 | 0.81 | F9 (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4301733-A1 | SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-01-10 | — | — | EP | disclosed |
| US-11771711-B2 | Substituted pyridines as DNMT1 inhibitors | GlaxoSmith Kline Intellectual Property Development Limited (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11771711-B2 | Substituted pyridines as DNMT1 inhibitors | GlaxoSmith Kline Intellectual Property Development Limited (GB) | 2023-10-03 | — | — | US | disclosed |
| WO-2022185160-A1 | SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771711-B2 | Substituted pyridines as DNMT1 inhibitors | DNMT1, DNMT3A, DNMT3B | CA2 4241/4885CA9 4215/4885CA1 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.